However, there are limited data regarding conditions that directly cause myeloma-related deaths. Objectives To study the underlying causes of death in patients with MM. Methods We performed a retrospective observational study using the CDC WONDER (Centers for Disease Control and Prevention Wide-Ranging...
Multiple myeloma represents about 1% of all cancers and 10–20% of all hematologic malignancies. The clonal proliferation of malignant plasma cells in the bone marrow may result both in local growth and in systemic effects due to the overproduction of a monoclonal protein (M-protein). Plasma cel...
The commonly assumed target, RB1, showed complete LOF in 3.2% of patients, while DIS3 complete LOF was detected in 6.9% of patients; however, a striking number of additional genes were independently knocked out in myeloma (Fig. 1b). The following two contiguous gene regions with complete ...
Multiple myeloma specialists compare step-up dosing practices and provide clinical insights on treating patients with multiple myeloma. This is a modal window. This video is either unavailable or not supported in this browser Error Code: MEDIA_ERR_SRC_NOT_SUPPORTED Technical details : The ...
Ashraf Z. Badros, MB, ChB, professor of medicine, director of the Multiple Myeloma Service, and vice chair of the Clinical Research Committee for the Program in Oncology at the University of Maryland School of Medicine in Baltimore, discusses the background, methods, and design of the phase...
A panel of experts discuss the evolving landscape of newly diagnosed multiple myeloma. This is a modal window. This video is either unavailable or not supported in this browser Error Code: MEDIA_ERR_SRC_NOT_SUPPORTED Technical details : The media could not be loaded, either because the ...
EP: 10.Transplant-Ineligible MM: Reinitiating Therapy EP: 11.Counseling Patients With MM About Treatment Duration EP: 12.Transplant-Ineligible MM: Navigating Treatment Challenges EP: 13.Management of Transplant-Ineligible Multiple Myeloma Robert Orlowski, MD, PhD:Let’s go to the next polling questi...
EP: 1.An Overview of Multiple Myeloma EP: 2.The Role of BCL-2 in Normal and Multiple Myeloma Cells EP: 3.Venetoclax Monotherapy for the Treatment of Multiple Myeloma EP: 4.Venetoclax plus Dexamethasone for Multiple Myeloma Treatment EP: 5.Venetoclax for Multiple Myeloma: The Phase 3 BELLINI...
Experts explore the evolving goals in treating newly diagnosed patients with multiple myeloma, including balancing effective therapies, achieving MRD-negative remission, and managing toxicities. This is a modal window. This video is either unavailable or not supported in this browser Error Code: MEDIA_...
[train] epochs = 100 batch_size = 4 patience = 10 metrics = ["binary_accuracy", "val_binary_accuracy"] model_dir = "./models" eval_dir = "./eval" image_datapath = "./MultipleMyeloma/train/images/" mask_datapath = "./MultipleMyeloma/train/masks/" ;2023/06/22 create_backup = Tru...